- Home
- KIO vs BCYC Comparison
KIO vs BCYC Comparison
Compare KIO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | BCYC |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 291.8M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KIO | BCYC |
|---|---|---|
| Price | $9.75 | $3.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 301.8K | ★ 483.4K |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $3.33 |
| 52 Week High | $12.18 | $9.08 |
Technical Indicators
Market Signals| Indicator | KIO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 27.89 | 44.13 |
| Support Level | N/A | $3.33 |
| Resistance Level | $11.22 | $3.99 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 5.15 | 18.70 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.